THE POPULARIZATION OF ORODISPERSIBLE TABLETS IN THE PHARMACEUTICAL MARKET

Ludmila Alvim Pinho, Ana Claudia Temer, Caroline Ribeiro, Livia Lira Sá-Barreto, Marcilio Sergio Soares Cunha-Filho

Resumo


Orodispersible tablets are getting popular due to its easy administration which leads to a higher therapeutic adherence. This study aimed to evaluate the state of the art of these drug products based on the scientific literature. Also, orodispersible tablets available in the US, Europe and Brazil markets based on information extracted from the health agencies were analyzed. Those tablets are designed to be placed on the tongue and instantly disintegrated by the fast capitation of the saliva without the additional intake of water. The orodispersible technology enables oral administration of tablets to patients with dysphagia, especially children, and elderlies. Moreover, orodispersible make possible rapid drug intervention and mouth absorption. The drug is partially absorbed in the oral cavity, pharynx, and esophagus without first pass effect, increasing drug bioavailability and reaching faster therapeutic effect. This is a low-cost technology that fits in a conventional solid production area and adds value to the product without requiring high investment. A market analysis showed there is a predominance of antihistamine drugs or medicines for mental disorders using orodispersible matrices. However, the orodispersible technology shows great versatility and potential application to other pharmacological groups. It is expected that in coming years a massive commercial insertion of this tablet technology occurs. In this scenery, it is indispensable that health professionals are prepared with updated technical information for the use of this therapeutic resource safely and efficiently.


Palavras-chave


orodispersible tablets; oral absorption; dysphagia; therapeutic adherence

Texto completo:

PDF (English)

Referências


Schuhmacher A, Gassmann O, Hinder M. Changing R&D models in research-based pharmaceutical companies. J Transl Med. 2016 Apr 27;14(1):105. doi: 10.1186/s12967-016-0838-4.

Park K. Controlled drug delivery systems: Past forward and future back. J Control Release. 2014 Sep 28;190:3-8. doi: 10.1016/j.jconrel.2014.03.054

Khanna I. Drug discovery in pharmaceutical industry: Productivity challenges and trends. Drug Discov Today. 2012 Oct;17(19-20):1088-102. doi: 10.1016/j.drudis.2012.05.007

Abbay F B, Ugurlu T. Orally Disintegrating Tablets: A Short Review. J Pharm Drug Devel 3(3): 303. doi: 10.15744/2348-9782.3.303

Teixeira MT, Sa-Barreto LCL, Mendonca Silva DL, Cunha Filho MSS. Overview of regulatory aspects guiding tablet scoring. Rev Panam Salud Publica. 2016 Jun;39(6):372-377.

Brasil. Vocabulário controlado de formas farmacêuticas, vias de administração e embalagens de medicamentos. In: Sanitária. Anvisa, editor. 1 ed. Brasília 2011.

British pharmacopoeia Volume III. London: Stationery Office; 2009.

Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and elderly. Eur J Pharm Sci. 2015 Jul 30;75:2-9. doi: 10.1016/j.ejps.2015.02.015.

Chowdary KPR, Shankar KR, Suchitra B. Recent Research on Orodispersible Tablets - a Review. Int Res J Pharm Appl Sci 2014;4(41):64-7364.

Scarpa M, Paudel A, Kloprogge F, Hsiao WK, Bresciani M, Gaisford S, Orlu M. Key acceptability attributes of orodispersible films. Eur J Pharm Biopharm. 2018 Apr;125:131-140. doi: 10.1016/j.ejpb.2018.01.003

Školáková T, Patera J, Zámostný P. Effect of polymer type on the surface energy of acetaminophen solid dispersions prepared by melt method. Int J Pharm. 2017 Sep 15;530(1-2):107-112. doi: 10.1016/j.ijpharm.2017.07.029

Petrovick GF, Kleinebudde P, Breitkreutz J. Orodispersible tablets containing taste-masked solid lipid pellets with metformin hydrochloride: Influence of process parameters on tablet properties. Eur J Pharm Biopharm. 2018 Jan;122:137-145. doi: 10.1016/j.ejpb.2017.10.018

Arora P, Sethi VA, Plot T, Knowledge N, P GN-U. Review Article Orodispersible Tablets : A Comprehensive Review. Int J Res Dev Pharm Life Sci. 2013;2(2):270-84.

Cilurzo F, Musazzi UM, Franzé S, Selmin F, Minghetti P. Orodispersible dosage forms: biopharmaceutical improvements and regulatory requirements. Drug Discov Today. 2018 Feb;23(2):251-259. doi: 10.1016/j.drudis.2017.10.003

Mistry P, Batchelor H. Evidence of acceptability of oral pediatric medicines: a review. J Pharm Pharmacol. 2017;69(4):361-76. doi: 10.1111/jphp.12610

Liew K Bin, Tan YTF, Peh KK. Taste-masked and affordable donepezil hydrochloride orally disintegrating tablet as promising solution for non-compliance in Alzheimer's disease patients. Drug Dev Ind Pharm. 2015 Apr;41(4):583-93. doi: 10.3109/03639045.2014.884130

Sevilla C, Jimenez-Caballero PE, Alfonso V. Orally disintegrating donepezil: are the main caregivers of patients with alzheimer's disease more satisfied with this formulation of donepezil than with the traditional one? Rev Neurol. 2009;49(9):451-7.

Novick D, Montgomery W, Treuer T, Koyanagi A, Aguado J, Kraemer S, et al. Comparison of clinical outcomes with orodispersible versus standard oral olanzapine tablets in nonadherent patients with schizophrenia or bipolar disorder. Patient Prefer Adherence. 2017;11:1019-25. doi: 10.2147/PPA.S124581

Navarro V. Improving medication compliance in patients with depression: Use of orodispersible tablets. Adv Ther. 2010 Nov;27(11):785-95. doi: 10.1007/s12325-010-0073-y.

Casian T, Bogdan C, Tarta D, Moldovan M, Tomuta I, Iurian S. Assessment of oral formulation-dependent characteristics of orodispersible tablets using texture profiles and multivariate data analysis. J Pharm Biomed Anal. 2018 Apr 15;152:47-56. doi: 10.1016/j.jpba.2018.01.040

Rameesa CK, Drisya MK. Orodispersible Tablet: A Patient Friendly Dosage Form (a Review). Bali Med Journal. 2015;4(1):17-20. doi:10.15562/bmj.v4i1.101

Divya P, Nagaraja TS, Yogananda R, Pharmacy SJMC. An Overview on Patented Technologies of Orodispersible Tablets. Int J drug Discov Herb Res. 2013;3(1):556-64.

iirainen A, Kokki M, Lidsle HM, Lehtonen M, Ranta VP, Kokki H. Absorption of ibuprofen orodispersible tablets in early postoperative phase - a pharmacokinetic study. Curr Med Res Opin. 2018 Apr;34(4):683-688. doi: 10.1080/03007995.2017.1394832.

Giri TK, Tripathi DK, Majumdar R. Formulation aspects in the development of orodispersible tablets: An overview. Int J Pharm Pharm Sci. 2010;2(3):38-42.

Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and elderly. Eur J Pharm Sci. 2015 Jul 30;75:2-9. doi: 10.1016/j.ejps.2015.02.015

Bala R, Khanna S, Pawar P, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013 Apr;3(2):67-76. doi: 10.4103/2230-973X.114897

Sonawane L V., Poul BN, Tippanbone PM. Formulation and evaluation of fast dissolving tablets of amlodipine besylate by using sublimation method. Lat Am J Pharm. 2016;35(3):481-8.

Pathan IB, Shingare PR, Kurumkar P. Formulation design and optimization of novel mouth dissolving tablets for venlafaxine hydrochloride using sublimation technique. J Pharm Res. 2013;593-8.

Repka MA, Majumdar S, Kumar Battu S, Srirangam R, Upadhye SB. Applications of hot-melt extrusion for drug delivery. Expert Opin Drug Deliv. 2008 Dec;5(12):1357-76. doi: 10.1517/17425240802583421

Pimparade MB, Morott JT, Park JB, Kulkarni VI, Majumdar S, Murthy SN, et al. Development of taste masked caffeine citrate formulations utilizing hot melt extrusion technology and in vitro-in vivo evaluations. Int J Pharm. 2015 Jun 20;487(1-2):167-76. doi: 10.1016/j.ijpharm.2015.04.030

Bangale GS, Shinde GJYG V, Rathinaraj BS. New Generation of Orodispersible Tablets : Recent Advances and Future Prospects. Int J pharmacutical science. 2011;1(2):52-62.

Ghareeb MM, Mohammedways TM. Preparation and characterization of orodispersible tablets of Meclizine Hydrochloride by wet granulation method. African J Pharm Pharmacol. 2013;7(28):1969-73. doi:10.5897/ajpp12.1269

Dixit AS, Kulkarni PK, Reddy SC. Methotrexate fast disintegrating tablet as a dosage form for dysphagia patients. Int J Pharm Pharm Sci. 2014;6(9):217-25.

Muñoz H, Castan H, Clares B, Ruiz MA. Obtaining fast dissolving disintegrating tablets with different doses of melatonin. Int J Pharm. 2014 Jun 5;467(1-2):84-9. doi: 10.1016/j.ijpharm.2014.03.054.

Katsuno E, Tahara K, Takeuchi Y, Takeuchi H. Orally disintegrating tablets prepared by a co-processed mixture of micronized crospovidone and mannitol using a ball mill to improve compactibility and tablet stability. Powder Technol. 2013;241:60-6. doi: 10.1016/j.powtec.2013.03.008

Da Cunha Filho MSS, Sá-Barreto LCL. Utilização de ciclodextrinas na formação de complexos de inclusão de interesse farmacêutico. Rev. Ciênc. Farm. Básica Apl. 2007; 28 (1):1-9

Pabari RM, Ramtoola Z. Application of face centred central composite design to optimise compression force and tablet diameter for the formulation of mechanically strong and fast disintegrating orodispersible tablets. Int J Pharm. 2012 Jul 1;430(1-2):18-25. doi: 10.1016/j.ijpharm.2012.03.021

Patil HG, Tiwari R V., Repka MA, Singh KK. Formulation and development of orodispersible sustained release tablet of domperidone. Drug Dev Ind Pharm. 2016;42(6):906-15.

Elwerfalli AM, Ghanchi Z, Rashid F, Alany RG, ElShaer A. New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook. Curr Drug Deliv [Internet]. 2015;12(6):652-67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25760951

Visser JC, Woerdenbag HJ, Hanff LM, Frijlink HW. Personalized Medicine in Pediatrics: The Clinical Potential of Orodispersible Films. AAPS PharmSciTech [Internet]. 2017;18(2):267-72. Available from: http://link.springer.com/10.1208/s12249-016-0515-1

Borges AF, Silva C, Coelho JFJ, Simões S. Oral films: Current status and future perspectives: I-Galenical development and quality attributes. J Control Release [Internet]. 2015;206:1-19. Available from: http://dx.doi.org/10.1016/j.jconrel.2015.03.006

Thabet Y, Lunter D, Breitkreutz J. Continuous manufacturing and analytical characterization of fixed-dose, multilayer orodispersible films. Eur J Pharm Sci. 2018;(2017).

Sieber D, Lazzari A, Quodbach J, Pein M. Applicability of two automated disintegration apparatuses for rapidly disintegrating (mini)tablets. Pharm Dev Technol. 2017;22(2):198-205.

Stoltenberg I, Breitkreutz J. Orally disintegrating mini-tablets (ODMTs) - A novel solid oral dosage form for pediatric use. Eur J Pharm Biopharm. 2011;78(3):462-9.

Patil HG, Tiwari R V., Repka MA, Singh KK. Formulation and development of orodispersible sustained release tablet of domperidone. Drug Dev Ind Pharm. 2016;42(6):906-15. doi: 10.3109/03639045.2015.1088864

Elwerfalli AM, Ghanchi Z, Rashid F, Alany RG, ElShaer A. New Generation of Orally Disintegrating Tablets for Sustained Drug Release: A Propitious Outlook. Curr Drug Deliv. 2015;12(6):652-67.

Visser JC, Woerdenbag HJ, Hanff LM, Frijlink HW. Personalized Medicine in Pediatrics: The Clinical Potential of Orodispersible Films. AAPS PharmSciTech. 2017 Feb;18(2):267-272. doi: 10.1208/s12249-016-0515-1

Borges AF, Silva C, Coelho JFJ, Simões S. Oral films: Current status and future perspectives: I-Galenical development and quality attributes. J Control Release. 2015 May 28;206:1-19. doi: 10.1016/j.jconrel.2015.03.006

Thabet Y, Lunter D, Breitkreutz J. Continuous manufacturing and analytical characterization of fixed-dose, multilayer orodispersible films. Eur J Pharm Sci. 2018 Feb 27;117:236-244. doi: 10.1016/j.ejps.2018.02.030

Sieber D, Lazzari A, Quodbach J, Pein M. Applicability of two automated disintegration apparatuses for rapidly disintegrating (mini)tablets. P Pharm Dev Technol. 2017 Mar;22(2):198-205. doi: 10.1080/10837450.2016.1189935

Technol. 2017 Mar;22(2):198-205. doi: 10.1080/10837450.2016.1189935

Stoltenberg I, Breitkreutz J. Orally disintegrating mini-tablets (ODMTs) - A novel solid oral dosage form for pediatric use. Eur J Pharm Biopharm. 2011 Aug;78(3):462-9. doi: 10.1016/j.ejpb.2011.02.005

Dockrill P. The FDA has just approved the first 3D-printed drug. 2015. Available from: http://www.sciencealert.com/the-fda-has-just-approved-the-first-3d-printed-drug.




DOI: http://dx.doi.org/10.14450/2318-9312.v30.e2.a2018.pp77-84

Apontamentos

  • Não há apontamentos.


Direitos autorais 2018 Ludmila Alvim Pinho, Ana Claudia Temer, Caroline Ribeiro, Livia Lira Sá-Barreto, Marcilio Sergio Soares Cunha-Filho

Licença Creative Commons
Este obra está licenciado com uma Licença Creative Commons Atribuição-NãoComercial-SemDerivações 4.0 Internacional.

Conselho Federal de Farmácia - CFF

SHIS QI 15 Lote "L" - Lago Sul - Brasília - DF

CEP: 71635-615 - Fone: (61)3878-8751

e-mail:infarma@cff.org.br

Infarma-Ciências Farmacêuticas

ISSN - 0104-0219 (Versão impressa)

ISSN - 2318-9312 (Versão eletrônica)

Indexadores: